"I’m sure someone’s lost their job," said the CEO of Sandoz, which has now filed to launch a generic GLP-1 in Canada next ...

They were designed to treat diabetes, then prescribed for weight loss, and now—as researchers are finding—they might hold the ...

WEIGHT loss jabs. including Mounjaro and Wegovy, have been linked to more than 100 deaths in the UK, new figures have revealed. But none of the fatalities are proven to have been caused directly ...

Novo Nordisk A/S shares are staging a comeback after a tumultuous year for the maker of Ozempic and Wegovy. The stock is up ...

Big drugmakers are abusing the drug patent process to generate extra revenue at the cost of patients, according to a new ...

Novo Nordisk (NYSE: NVO) has permanently forfeited Canadian patent protection for semaglutide—the blockbuster active ...

While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, ...

Find out if Novo's GLP-1 patent expiring in Canada is a mistake or a calculated move. Did the firm lose exclusivity over a ...

We have recently begun acquiring a new position in Novo Nordisk. Click here for our investment thesis on NVO stock.

Eli Lilly's drug, called eloralintide, helped some patients lose more than 11% of their body weight in three months.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Gov. Josh Shapiro’s administration plans to save money by cutting poor patients’ access to expensive weight-loss drugs like ...